Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Cilofexor (Primary) ; Firsocostat (Primary) ; Selonsertib (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ATLAS
- Sponsors Gilead Sciences
- 14 Nov 2023 Results assessing Increased Cardiovascular and Kidney Disease Risk in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 08 Nov 2022 Results (n=198) assessing the changes of plasma proteome markersin patients with NASH via SomaScan, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 01 Nov 2022 According to a Gilead Sciences media release, data from the trial will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.